Hematologic Oncology

The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.

Overall survival was the sole US primary end point of the phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab and was not met.

Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.

Johannes Schetelig, MD, MSc, discusses data for anti–T-lymphocyte globulin vs post-transplant cyclophosphamide for GVHD prophylaxis in hematologic malignancies.

Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.

Lorenzo Falchi, MD, discusses key unmet needs and important next steps for diffuse large B-cell lymphoma research.

Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.

The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.

Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

Ruxolitinib plus extracorporeal photopheresis drove responses in steroid-refractory or -dependent chronic graft-vs-host disease.

Elias Jabbour, MD, discusses the significance of the FDA approval of orally disintegrating nilotinib tablets for chronic myeloid leukemia.

Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for untreated classical Hodgkin lymphoma.

Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress

The European Commission has approved epcoritamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma.

The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.

Everett Meyer, MD, PhD, discusses the significance of the FDA approval of Orca-T for patients with hematologic malignancies.

The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.

At the 6th World Congress of Cutaneous Lymphoma, a group of world-leading CTCL expert consider what the field will abandon in the next decade.

Both annamycin-containing arms produced numerically higher CR and CRc rates vs cytarabine alone in relapsed/refractory AML.

Romiplostim N01 supported platelet engraftment after unrelated umbilical cord blood transplantation with no serious TRAEs in hematologic malignancies.

Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine and cedazuridine plus venetoclax in acute myeloid leukemia.

Lena Specht, MD, DMSc, discusses data for mogamulizumab in Danish patients with mycosis fungoides or Sezary syndrome and their effect on clinical practice.